BlackRock Global Funds - World Healthscience Fund A2 SGD HedgedRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 11.0 | 12.9 | 6.6 | -3.8 | 6.5 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 17/04/2024 | SGD 22.16 | |
Day Change | 0.29% | |
Morningstar Category™ | Other Equity | |
ISIN | LU1057294990 | |
Fund Size (Mil) 28/03/2024 | USD 14214.93 | |
Share Class Size (Mil) 17/04/2024 | SGD 180.19 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 09/02/2023 | 1.79% |
Investment Objective: BlackRock Global Funds - World Healthscience Fund A2 SGD Hedged |
The Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance (“ESG”) investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Xiang Liu 01/06/2020 | ||
Erin Xie 01/04/2011 | ||
Inception Date 30/04/2014 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care NR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BlackRock Global Funds - World Healthscience Fund A2 SGD Hedged | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 7.30 |
Novo Nordisk A/S Class B | Healthcare | 7.09 |
UnitedHealth Group Inc | Healthcare | 6.64 |
AbbVie Inc | Healthcare | 4.78 |
Merck & Co Inc | Healthcare | 4.51 |
Increase Decrease New since last portfolio | ||
BlackRock Global Funds - World Healthscience Fund A2 SGD Hedged |